Neuronal DNA damage correlates with a positive detection of c-Jun, nuclear factor κB, p53 and Par-4 transcription factors in Alzheimer's disease;El daño nuclear neuronal se correlaciona con la detección in situ de los factores de transcripción c-Jun, factor nuclear κb, p53 y Par-4 en la enfermedad de Alzheimer

Revista de Neurologia

Volumn 36, Issue 11, 2003, Pages 1004-1010

  Garcia Ospina G P ^a   Jimenez Del Rio M ^a   Lopera, F ^a   Vélez Pardo, Carlos ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Alzheimer; c Jun; p53; Par 4; TUNEL

Indexed keywords

ALPHA,BETA PROTEIN[25-65]; AMYLOID BETA PROTEIN; CARRIER PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PAR 4 PROTEIN; PAR-4 PROTEIN; PROTEIN; PROTEIN C JUN; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 4; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN CORTEX; CELL DEATH; CHEMISTRY; CLINICAL ARTICLE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE SEVERITY; DNA DAMAGE; FEMALE; GLIOSIS; HUMAN; HUMAN TISSUE; MALE; METABOLISM; NERVE CELL; NERVE CELL LESION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NICK END LABELING; PATHOLOGY; PHYSIOLOGY; SENILE PLAQUE; SIGNAL TRANSDUCTION;

EID: 0041304626     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3611.2002533     Document Type: Article

References (47)

1. Howlett DR, Allsop D, Karran EH. The biology and molecular neuropathology of b-amyloid protein. In Dawbarn D, Allen SJ, eds. Neurobiology of Alzheimer's disease. Oxford: Oxford University Press; 2001. p. 75-102.
2. Wischik CM, Theuring F, Harrington CH-R. The molecular basis of tau protein pathology in Alzheimer's disease and related neurodegenerative dementias. In Dawbarn D, Allen SJ, eds. Neurobiology of Alzheimer's disease. Oxford: Oxford University Press; 2001. p. 103-206.
3. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
4. DeLeon MJ, Convit A, Tarshish CH, DeSanti S, Bobinski M. MRI studies of the hippocampal formation: contributions to the early diagnosis of Alzheimer's disease. In DeLeon MJ. An atlas of Alzheimer's disease. New York: The Parthenon Publishing Group; 1999. p. 31-55.
5. Lewis J, Dickson DW, Lin W-L, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 2001; 293: 1487-91.
6. Gotz J, Chen F, Dorpe JV, Nitsch RM. Formation of neurofibrillary tangles in P301 L Tau transgenic mice induced by Ab42 fibrils. Science 2001; 293: 1491-5.
7. Butterfield DA, Griffin S, Munch G, Pasinetti GM. Amyloid b-peptide and amyloid pathology are central to oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimer's disease 2002; 4: 193-201.
8. Smith M, Perry G. Molecular and cellular aspects of oxidative damage in Alzheimer's disease. In Poli G, Cadenas C, Packer L, eds. Free radicals in brain pathophysiology. New York: Marcel Dekker; 2000. p. 313-21.
9. Estus S, Borchelt D, Kindy MS, Vassar R. Ab deposition is essential to AD neuropathology. J Alzheimer's disease 2002; 4: 133-8.
10. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid b-protein. J Alzheimer's disease 2001; 3: 75-81.
11. Cotman CW, Tong L, Anderson A, Cribss D, Su J. b-amyloid toxicity: diverse biological activities drive multiple cellular mechanisms. In Iqbal K, Sisodia SS, Winblad B, eds. Alzheimer's disease: Advances in etiology, pathogenesis, and therapeutics. New York: John Wiley & Sons, Ltd; 2001. p. 407-20.
12. Miranda S, Opazo C, Larrondo LF, Muñoz FJ, Ruiz F, Leighton F. The role of oxidative stress in the toxicity induced by amyloid b-peptide in Alzheimer's disease. Prog Neurobiol 2000; 62: 633-48.
13. 2), caspase-3, NF-kappa B, p53 and c-Jun. Neurotoxicology 2002; 23: 351-65.
14. Mielke K, Herdegen T. JNK and p38 stress kinases-degenerative effectors of signal transduction-cascades in the nervous system. Prog Neurobiol 2000; 61: 45-60.
15. Okazawa H, Estus S. The JNK/c-Jun cascade and Alzheimer's disease. Am J Alzheimer's Dis Other Demen 2002; 17: 79-88.
16. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-ℏB is activated in primary neurons by amyloid b peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci 1997; 94: 2642-7.
17. Ferrer I, Martí E, López E, Tortosa A. NF-κB immunoreactivity is observed in association with beta A4 diffuse plaques in patients with Alzheimer's disease. Neuropathol Appl Neurobiol 1998; 24: 271-7.
18. Lukiw WJ, Bazan NG. Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 1998; 53: 583-92.
19. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol 1997; 56: 86-93.
20. MacGibbon GA, Lawlor PA, Walton M, Sirimanne E, Faull RLM, Synek B, et al. Expression of Fos, Jun and Krox family proteins in Alzheimer's disease. Exp Neurol 1997; 147: 316-32.
21. Jellinger KA, Stadelmann CH. Problems of cell death in neurodegeneration and Alzheimer's disease. J Alzheimer's Disease 2001; 3: 31-40.
22. Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, et al. Par-4 is a mediator of neuronal degeneration associate with the pathogenesis of Alzheimer's Disease. Nat Med 1998; 4: 957-62.
23. Vélez-Pardo C, Lopera F, Jiménez Del Río M. DNA damage does not correlate with beta-plaques and neurofibrillary tangles in Familial Alzheimer's disease Presenilin-1 [E280A] mutation. J Alzheimer's Disease 2000; 2: 47-57.
24. Hyman BD, Trojanowski JQ. Editorial on consensus recommendations for the post-mortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 1095-7.
25. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neurophatologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
26. Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, et al. Amyloid-b peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21: 1-5.
27. Kienlen-Campard P, Miolet S, Tasiaux B, Octave J-N. Intracellular amyloid b-1-42, but not extracellular soluble amyloid-b peptides, induces neuronal apoptosis. J Biol Chem 2002; 277: 15666-70.
28. Chui DH, Dobo E, Makifuchi T, Akiyama H, Kawakatsu S, Petit A, et al. Apoptotic neurons in Alzheimer's disease frequently show intracellular Ab42 labeling. J Alzheimer's Disease 2001; 3: 231-9.
29. Kihiko M, Tucker HM, Rydel RE, Estus S. c-Jun contributes to amyloid b-induced neuronal apoptosis but is not necessary for amyloid b-induced c-jun induction. J Neurochem 1999; 73: 2609-12.
30. Jiménez Del Rio M, Vélez-Pardo C. La apoptosis en las enfermedades neurodegenerativas: evidencias y controversias. Rev Neurol 2001; 32: 851-60.
31. Lucassen PJ, Chung WCJ, Kamphorst W, Swaab DF. DNA damage distribution in the human brain as shown by in situ end labeling: Area-specific differences in aging and Alzheimer's disease in the absence of apoptotic morphology. J Neuropathol Exp Neurol 1997; 56: 887-900.
32. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 1995; 133: 225-30.
33. Graeber MB, Moran LB. Mechanisms of cell death in Neurodegenerative diseases: fashion, fiction, and facts. Brain Pathol 2002; 12: 385-90.
34. Gopa M. Apoptosis. Detection of Apoptotic Cells. Promega Notes 1996; 57: 10-5.
35. Perry G, Nunomura A, Smith MA. A suicide note from Alzheimer's disease neurons? Nat Med 1998; 4: 897-8.
36. Perry G, Nunomura A, Luchasen P, Lassmann H, Smith MA. Apoptosis and Alzheimer's disease. Science 1998; 282: 268-9.
37. Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanism. Nat Rev Mol Cell Biol 2001; 2: 1-10.
38. Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol 2001; 2: 545-50.
39. Sloviter RS. Apoptosis: a guide for the perplexed. Trends Pharmacol Sci 2002; 23: 19-24.
40. LaFerla F, Hall CK, Ngo L, Jay G. Extracellular deposition of b-amyloid upon p53-dependent neuronal cell death in transgenic Mice. J Clin Invest 1996; 98: 1626-32.
41. De la Monte SM, Sohn YK, Wands JR. Correlates of p53 and Fas (CD95) mediate apoptosis in Alzheimer's disease. J Neurol Sci 1997; 152: 73-83.
42. Xie J, Chang X, Guo Q. Aberrant induction of Par-4 is involved in apoptosis of hippocampal neurons in presenilin-1 M146V mutant knock-in mice. Brain Res 2001; 915: 1-10.
43. Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, et al. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 2002; 62: 1768-75.
44. Anderson AJ, Pike CJ, Colman C. Differential induction of immediate early gene proteins in cultured neurons by b-amyloid (Ab): association of c-Jun with Ab-induced apoptosis. J Neurochem 1995; 65: 1487-98.
45. Estus S, Zaks W, Freeman R, Gruda M, Bravo R, Johnson E. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 1994; 127: 1717-27.
46. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
47. Kerr JFR, Gobe GC, Winterford CM, Harmon BV. Anatomical methods in cell death. In Schwartz LM, Osborne BA, eds. Methods in cell biology: cell death. New York: Academic Press; 1995. p. 1-27.